Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group
Open Access
- 11 April 2018
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 21 (5), 493-500
- https://doi.org/10.1016/j.jval.2018.03.004
Abstract
No abstract availableKeywords
This publication has 82 references indexed in Scilit:
- Ten Common Questions (and Their Answers) About Off-label Drug UseMayo Clinic Proceedings, 2012
- Estimating the budget impact of orphan medicines in Europe: 2010 - 2020Orphanet Journal of Rare Diseases, 2011
- When Ethics Constrains Clinical Research: Trial Design of Control Arms in “Greater Than Minimal Risk” Pediatric TrialsHuman Gene Therapy, 2011
- Pricing and reimbursement of orphan drugs: the need for more transparencyOrphanet Journal of Rare Diseases, 2011
- Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTRMutationNew England Journal of Medicine, 2010
- Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB)Contemporary Clinical Trials, 2010
- Clinical research for rare disease: Opportunities, challenges, and solutionsMolecular Genetics and Metabolism, 2009
- Off-Label Prescribing: A Call for Heightened Professional and Government OversightThe Journal of Law, Medicine & Ethics, 2009
- Differential diagnosis of suspected multiple sclerosis: a consensus approachMultiple Sclerosis Journal, 2008
- Drugs for exceptionally rare diseases: do they deserve special status for funding?QJM: An International Journal of Medicine, 2005